"A new consumer-friendly form ( is now available for making reports to MedWatch, the Food and Drug Administration's (FDA) on-line system for collecting information about serious problems with drugs, medical devices and other FDA-"...
Clinical consequences of overdose with OMNISCAN (gadodiamide) have not been reported. The minimum lethal dose of intravenously administered OMNISCAN (gadodiamide) in rats and mice is greater than 20 mmol/kg (200 times the recommended human dose of 0.1 mmol/kg; 67 times the cumulative 0.3 mmol/kg dose). OMNISCAN (gadodiamide) is dialyzable.
OMNISCAN (gadodiamide) is contraindicated in patients with:
- chronic, severe kidney disease (glomerular filtration rate, GFR < 30 mL/min/1.73m²), or
- acute kidney injury.
Last reviewed on RxList: 2/11/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Omniscan Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.